Physician profile
David Dionisio
NPI 1750589875
$3,080.09
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,274 · 2020: $1,009 · 2021: $660 · 2024: $137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $136.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $454.39 | 2019-2021 | |
| Pfizer INC. | $303.95 | 2019-2021 | |
| Amgen INC. | $291.40 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $251.99 | 2019-2021 | |
| Amarin Pharma, INC. | $197.75 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $190.50 | 2019-2021 | |
| Lilly USA, LLC | $147.90 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $139.87 | 2019-2021 | |
| Abbott Laboratories | $136.85 | 2024 | Freestyle Libre 3 |
| Astellas Pharma US INC | $122.36 | 2019-2021 | |
| Glaxosmithkline, LLC. | $110.21 | 2019-2021 | |
| Esperion Therapeutics, INC. | $95.54 | 2020-2021 | |
| Allergan, INC. | $79.64 | 2019-2021 | |
| Horizon Therapeutics Plc | $71.96 | 2019-2021 | |
| Sanofi Pasteur INC. | $57.92 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.72 | 2020-2021 | |
| Seqirus USA INC | $52.94 | 2019-2021 | |
| Abbvie INC. | $50.72 | 2021 | |
| Sanofi-Aventis U.S. LLC | $49.80 | 2019-2021 | |
| Gilead Sciences, INC. | $42.77 | 2019 | |
| Merck Sharp & Dohme LLC | $34.39 | 2019 | |
| Hikma Pharmaceuticals USA | $30.84 | 2019-2020 | |
| Qiagen, LLC | $21.89 | 2020 | |
| Optos, INC. | $20.98 | 2020 | |
| Novartis Pharmaceuticals Corporation | $20.67 | 2021 | |
| Eisai INC. | $16.06 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $15.15 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Dionisio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.